I
33.95
0.97 (2.94%)
| Previous Close | 32.98 |
| Open | 32.95 |
| Volume | 355,139 |
| Avg. Volume (3M) | 2,590,300 |
| Market Cap | 4,244,579,584 |
| Price / Earnings (TTM) | 34.64 |
| Price / Earnings (Forward) | 10.91 |
| Price / Sales | 3.52 |
| Price / Book | 145.25 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Profit Margin | -5.30% |
| Operating Margin (TTM) | 25.56% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | -6.30% |
| Quarterly Earnings Growth (YOY) | -23.00% |
| Current Ratio (MRQ) | 0.880 |
| Operating Cash Flow (TTM) | 135.00 M |
| Levered Free Cash Flow (TTM) | 264.88 M |
| Return on Assets (TTM) | 12.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Indivior PLC | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.02% |
| % Held by Institutions | 89.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Two Seas Capital Lp | 30 Sep 2025 | 10,504,152 |
| Madison Avenue Partners, Lp | 30 Sep 2025 | 6,463,585 |
| Newtyn Management, Llc | 30 Sep 2025 | 4,200,000 |
| Divisadero Street Capital Management, Lp | 30 Sep 2025 | 3,362,605 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 48.00 (HC Wainwright & Co., 41.38%) | Buy |
| Median | 44.50 (31.08%) | |
| Low | 41.00 (Piper Sandler, 20.77%) | Buy |
| Average | 44.50 (31.08%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 31.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Jan 2026 | 48.00 (41.38%) | Buy | 34.56 |
| 30 Oct 2025 | 35.00 (3.09%) | Buy | 29.13 | |
| Piper Sandler | 31 Oct 2025 | 41.00 (20.77%) | Buy | 29.37 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |